Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-FAPI PET/CT in Malignant Tumors
Sponsor: Zhongnan Hospital
Summary
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP inhibitor (68Ga-FAPI), has been developed and used for visualization of tumor stroma by targeting FAP. Recent studies show favorable diagnosis efficiency in a variety of tumors, especially in gastrointestinal cancer, but the previous studies were all small-sample data or case reports. Therefore, further large-size research is necessary to confirm the advantages of 68Ga-FAPI in various of malignant tumors.
Official title: The Diagnostic Efficiency of 68Ga-FAPI PET/CT in Malignant Tumors
Key Details
Gender
All
Age Range
18 Years - 88 Years
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2021-02-23
Completion Date
2025-12-31
Last Updated
2025-06-05
Healthy Volunteers
Yes
Interventions
68Ga-FAPI
68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq/kg).
PET/CT
68Ga-FAPI PET/CT scan were performed 20\~60 min after 68Ga-FAPI (1.85-3.7MBq/kg) injection intravenously.
Locations (1)
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China